Clinical Trials
74 trialsNCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00448240 2025-03-18
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Henry Ford Health System
Phase 2/3 Terminated
NCT00503971 2025-03-07
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Phase 1/2 Terminated
NCT01032070 2024-12-12
PETEY
Astellas Pharma Inc
Phase 2 Terminated
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT01247922 2024-12-06
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Astellas Pharma Inc
Phase 2 Terminated
NCT02495233 2024-11-27
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
NCT00597597 2023-05-17
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Rush University Medical Center
Phase 2 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01683422 2021-08-10
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
Phase NA Terminated
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT00570258 2021-03-30
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
University of Arkansas
Phase 2 Terminated
NCT00760929 2021-01-05
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Hoffmann-La Roche
Phase 2 Terminated
NCT02318368 2020-10-22
FOCAL
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT01038856 2020-08-24
OSI-TAR-766
University of Oklahoma
Phase 2 Terminated
NCT01857271 2020-07-08
EVENT
Albert Einstein College of Medicine
Phase 2 Terminated
NCT02169284 2020-07-07
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT02926638 2020-03-19
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
SWOG Cancer Research Network
Phase 2/3 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02770014 2019-11-22
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01182350 2019-09-04
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01822496 2019-08-05
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00503841 2019-04-30
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Terminated
NCT00996502 2019-03-27
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Columbia University
Phase 1/2 Terminated
NCT00750555 2019-02-26
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Geisinger Clinic
Phase 2 Terminated
NCT01962896 2019-02-26
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00573989 2019-01-03
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Wake Forest University Health Sciences
Phase 1/2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00281021 2018-03-29
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
University of Louisville
Phase 2 Terminated
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT00592007 2017-06-06
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
University of California, San Diego
Phase 2 Terminated
NCT00841035 2017-05-19
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
Phase 2 Terminated
NCT00392665 2017-04-13
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Massachusetts General Hospital
Phase 2 Terminated
NCT01059305 2017-04-04
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00351039 2017-03-23
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01108458 2017-03-03
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Stanford University
Phase 2 Terminated
NCT00470535 2017-02-23
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01026844 2017-01-30
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital
Phase 1 Terminated